Heart failure
Conditions
Interventions
Observation Group for Heart Failure treatment:None
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 85 years old, clinically diagnosed with HFrEF (left ventricular ejection fraction LVEF =4 weeks (including at least two of the quadruple drugs of ARNI/ACEI/ARB, beta-blockers, MRA and SGLT2i) 3. Baseline systolic blood pressure >=85 mmHg and no severe hemodynamic instability
Exclusion criteria
Exclusion criteria: 1. Acute myocardial infarction, stroke or cardiogenic shock has occurred within the past three months; 2. Severe liver and kidney dysfunction (eGFR 3 times the upper limit of normal); 3. Known to be allergic to or have contraindications to viliciqua; 4. Patients with an expected lifespan of less than one year; 5. Survivors of cardiac arrest remain in a coma. 6. Severe bradycardia or tachycardia; 7. Patients with shock caused by pulmonary embolism or pericardial tamponade; 8. Hypertrophic cardiomyopathy; 9. Moderate to severe aortic insufficiency; 10. Aortic dissection, moderate to severe aortic reflux; 11. Uncontrollable bleeding within the past six months; 12. Patients with malignant tumors or those with serious diseases such as malignant tumors, with an expected lifespan of less than one year; 13. Pregnant and lactating women; 14. Neuropsychiatric disorders, unable to cooperate with management; 15. Participated in other clinical trials in the past year; 16. Other circumstances that the researcher deems unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 14-day dose compliance rate;Absolute improvement in left ventricular ejection fraction (LVEF) at 20 weeks compared to baseline (%); | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality;Readmission rate for heart failure; | — |
Countries
China
Contacts
Public ContactWushi Wang
The First Hospital of Jilin University
Outcome results
None listed